利邦財富管理有限公司購買輝瑞新股。(紐約證券交易所代碼：PFE)

Trinity Wealth Management LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,420 shares of the biopharmaceutical company's stock, valued at approximately $281,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. State Street Corp lifted its stake in Pfizer by 1.8% during the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company's stock valued at $16,818,434,000 after purchasing an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Pfizer by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company's stock valued at $5,952,333,000 after acquiring an additional 1,471,980 shares during the period. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $3,351,891,000. Nuveen Asset Management LLC raised its holdings in shares of Pfizer by 18.0% during the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company's stock valued at $1,658,518,000 after acquiring an additional 4,278,167 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Pfizer by 4.8% during the fourth quarter. Parametric Portfolio Associates LLC now owns 21,690,848 shares of the biopharmaceutical company's stock valued at $1,280,845,000 after acquiring an additional 985,096 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.

Get

Pfizer

alerts:

In other news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares of the company's stock, valued at approximately $760,732. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,126 shares of company stock valued at $2,075,003. Insiders own 0.05% of the company's stock.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley started coverage on shares of Pfizer in a report on Wednesday, April 6th. They set an "equal weight" rating and a $55.00 price target on the stock. JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research note on Tuesday, June 28th. SVB Leerink started coverage on shares of Pfizer in a research note on Monday, May 23rd. They issued a "market perform" rating and a $55.00 price objective on the stock. Wells Fargo & Company dropped their price objective on shares of Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Finally, Citigroup boosted their target price on shares of Pfizer from $46.00 to $57.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 5th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $57.26.

NYSE PFE opened at $52.31 on Tuesday. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The company has a fifty day simple moving average of $50.73 and a 200 day simple moving average of $51.98. The company has a market cap of $293.51 billion, a P/E ratio of 12.00, a P/E/G ratio of 0.63 and a beta of 0.73. Pfizer Inc. has a 1 year low of $38.93 and a 1 year high of $61.71.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). The firm had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. Pfizer's quarterly revenue was up 76.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 6.63 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date is Thursday, July 28th. Pfizer's dividend payout ratio (DPR) is presently 36.70%.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• Two Pet Health Stocks To Watch And One To Avoid
• PetVivo Holdings Is A Growth Stock Worth a Look
• PVH Corp Stock Approaching Key Support Levels
• 5 Reasons to Climb Aboard Carnival Stock
• Three (3) Top-Rated Dividend Payers Worth Your Attention

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.